Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.8 HKD | +4.46% | +8.74% | -49.91% |
10:13am | WuXi Shares Volatile as U.S. Bill Revised to Set Deadline for Decoupling | DJ |
10/05 | U.S. bill to restrict WuXi AppTec, other Chinese biotech cos revised to give more time to cut ties | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-49.91% | 17.58B | - | ||
+3.91% | 109B | B+ | ||
+10.87% | 105B | B+ | ||
+0.44% | 22.25B | B | ||
-13.14% | 22.09B | B+ | ||
-7.96% | 18.68B | A- | ||
-10.66% | 16.85B | B | ||
+3.75% | 13.76B | C+ | ||
+36.70% | 12.46B | C+ | ||
+295.70% | 8.12B | - | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 603259 Stock
- 2359 Stock
- Ratings WuXi AppTec Co., Ltd.